drugset / Trial / NCT01014481
Appropriate Timing of HAART in Co-infected HIV/TB Patients
Phase 4
Terminated
156 enrolled
Bamrasnaradura Infectious Diseases Institute
Mahidol University · collabThai Red Cross AIDS Research Centre · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To study the optimal timing to initiate antiretroviral therapy in HIV-infected patients who are receiving tuberculosis treatment between at 4 weeks and at 12 weeks after tuberculosis treatment by comparing the composite end point of death rate, hospitalization rate and adverse drug reactions at week 48, 96 and 144.
Timeline
- Start
- 2009-10
- Primary completion
- 2011-05
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 600 mg | — |
| Subject | Lamivudine | Other / unclassified | 300 mg | — |
| Subject | Tenofovir | Small molecule | 300 mg | — |